Neighbor communities in drug combination networks characterize synergistic effect.
暂无分享,去创建一个
Jun Zou | Pan Ji | Lin-Li Li | Sheng-Yong Yang | Ying-Lan Zhao | Yu-Quan Wei | Yu-Zong Chen | P. Ji | Lin-Li Li | Yuquan Wei | Jun Zou | Ying-Lan Zhao | S. Yang | Yu-Zong Chen | Linli Li
[1] Xin Chen,et al. DCDB: Drug combination database , 2010, Bioinform..
[2] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[3] Anagha Joshi,et al. Enrichment and aggregation of topological motifs are independent organizational principles of integrated interaction networks. , 2011, Molecular bioSystems.
[4] U. Alon,et al. Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.
[5] Hui Zhang,et al. An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs , 2009, Artif. Intell. Medicine.
[6] Holger Fröhlich,et al. GOSim – an R-package for computation of information theoretic GO similarities between terms and gene products , 2007, BMC Bioinformatics.
[7] Joshua D. Knowles,et al. Efficient discovery of anti-inflammatory small molecule combinations using evolutionary computing , 2011, Nature chemical biology.
[8] Eric B Haura,et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Xue-Gang Yang,et al. In silico prediction and screening of γ‐secretase inhibitors by molecular descriptors and machine learning methods , 2009, J. Comput. Chem..
[10] Lennart Martens,et al. The Protein Identifier Cross-Referencing (PICR) service: reconciling protein identifiers across multiple source databases , 2007, BMC Bioinformatics.
[11] Xing-Ming Zhao,et al. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..
[12] Dexter T. Duncan,et al. Relating protein adduction to gene expression changes: a systems approach. , 2011, Molecular bioSystems.
[13] Christian Sillaber,et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. , 2010, Cancer research.
[14] A. Barabasi,et al. Interactome Networks and Human Disease , 2011, Cell.
[15] B Xie,et al. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.
[16] Alan Ashworth,et al. Translating cancer research into targeted therapeutics , 2010, Nature.
[17] Marc Ferrer,et al. Parsimonious discovery of synergistic drug combinations. , 2011, ACS chemical biology.
[18] Gianni Panagiotou,et al. Mapping the genome of Plasmodium falciparum on the drug-like chemical space reveals novel anti-malarial targets and potential drug leads. , 2012, Molecular bioSystems.
[19] Bo Zhang,et al. A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.
[20] Xiaobo Zhou,et al. An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data , 2011, Bioinform..
[21] Elie Dolgin. When it takes two to tango, FDA suggests a new regulatory dance , 2011, Nature Medicine.
[22] Yan Zhou,et al. Evaluation of GO-based functional similarity measures using S. cerevisiae protein interaction and expression profile data , 2008, BMC Bioinformatics.
[23] David J. Harrison,et al. Systems pathology—taking molecular pathology into a new dimension , 2009, Nature Reviews Clinical Oncology.
[24] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[25] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[26] Ines Gockel,et al. Analysis of anti‐proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi‐receptor tyrosine kinase pathways , 2009, International journal of cancer.
[27] Yu-Quan Wei,et al. Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers , 2011, PloS one.
[28] Kara Dolinski,et al. The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..
[29] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..
[30] Livia Perfetto,et al. MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..
[31] L. Lai,et al. Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.
[32] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[33] Hanbing Rao,et al. Identification of small molecule aggregators from large compound libraries by support vector machines , 2009, J. Comput. Chem..
[34] Trey Ideker,et al. Integrating physical and genetic maps: from genomes to interaction networks , 2007, Nature Reviews Genetics.
[35] Sumithra J. Mandrekar,et al. Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.
[36] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[37] P. Sorger,et al. Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.
[38] J. Woodcock,et al. Development of novel combination therapies. , 2011, The New England journal of medicine.
[39] Michelle S. Scott,et al. Chemogenomic profiling predicts antifungal synergies , 2009, Molecular systems biology.
[40] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[41] Michael Costanzo,et al. Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.
[42] Robert Clarke,et al. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells , 2011, Nature Reviews Cancer.
[43] Alona Muzikansky,et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] D. Lauffenburger,et al. Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.
[45] T. Gilmer,et al. Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells , 2011, Molecular Cancer Therapeutics.
[46] Susumu Goto,et al. KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..
[47] Chih-Jen Lin,et al. Working Set Selection Using Second Order Information for Training Support Vector Machines , 2005, J. Mach. Learn. Res..
[48] Yu-Quan Wei,et al. Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry. , 2011, Molecular bioSystems.
[49] C. Sander,et al. Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.
[50] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[51] Bo Zhang,et al. Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.
[52] Rafael C. Jimenez,et al. The IntAct molecular interaction database in 2012 , 2011, Nucleic Acids Res..
[53] Jian Jin,et al. Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.
[54] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.